We posit that we avoided mimicking systemic hypertension that would be elicited by direct actions of peripheral administration of Ang II or direct effects of Ang II on the heart (Regan et al., 2015), as targeting this form of systemic hypertension has failed in clinical trials (Pitt et al., 2014). This evidence concerns the gene AGT and Hypertension.